Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
Tuesday, January 30, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is advancing its research on NX-2127, an orally bioavailable degrader of Bruton’s Tyrosine Kinase. This compound shows promise for treating patients with B cell malignancies. The company aims to leverage novel scientific insights to develop breakthrough therapies targeting cancer and autoimmune diseases.
Price reaction · baseline $8.37 (2024-01-29 close) · hit pre-market · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-4.5%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on innovative therapies for cancer and autoimmune diseases.
Development of NX-2127 as a potential treatment for B cell malignancies.
Emphasis on translating scientific insights into clinical applications.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-2127?
NX-2127 is an orally bioavailable degrader of Bruton’s Tyrosine Kinase.
What conditions does NX-2127 target?
NX-2127 is being developed for the treatment of B cell malignancies.
What is Nurix's focus?
Nurix focuses on translating scientific insights into therapies for cancer and autoimmune diseases.